Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
The facility sets a new benchmark in respiratory diagnostics
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
Fertility platform launches flagship clinic with advanced IVF tech
Subscribe To Our Newsletter & Stay Updated
